Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study
Prof Shaji K Kumar MD, Prof Simon J Harrison PhD, Prof Michele Cavo MD, Prof Javier de la Rubia MD, Rakesh Popat FRCPath, Prof Cristina Gasparetto MD, Prof Vania Hungria MD, Hans Salwender MD, Prof Kenshi Suzuki MD, Prof Inho Kim MD, Maika Onishi MD, Grace Ku MD, Rajvineeth Pothacamury MD, Muhammad Jalaluddin PhD, Jiewei Zeng PhD, Jeremy A Ross PhD, Edyta Dobkowska MD, Prof Philippe Moreau MD
{"title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study","authors":"Prof Shaji K Kumar MD, Prof Simon J Harrison PhD, Prof Michele Cavo MD, Prof Javier de la Rubia MD, Rakesh Popat FRCPath, Prof Cristina Gasparetto MD, Prof Vania Hungria MD, Hans Salwender MD, Prof Kenshi Suzuki MD, Prof Inho Kim MD, Maika Onishi MD, Grace Ku MD, Rajvineeth Pothacamury MD, Muhammad Jalaluddin PhD, Jiewei Zeng PhD, Jeremy A Ross PhD, Edyta Dobkowska MD, Prof Philippe Moreau MD","doi":"10.1016/s2352-3026(25)00139-5","DOIUrl":null,"url":null,"abstract":"The phase 3 BELLINI primary endpoint was met, showing superior progression-free survival with venetoclax versus placebo plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma as assessed by an independent review committee. However, venetoclax showed increased early mortality. Here, we report the final overall survival analysis.","PeriodicalId":501011,"journal":{"name":"The Lancet Haematology","volume":"10 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Haematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s2352-3026(25)00139-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The phase 3 BELLINI primary endpoint was met, showing superior progression-free survival with venetoclax versus placebo plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma as assessed by an independent review committee. However, venetoclax showed increased early mortality. Here, we report the final overall survival analysis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
